萨罗格利塔扎尔4毫克在代谢功能障碍相关的脂肪性肝病:从第四阶段研究的24周结果
Arun Sanyal1, Soham Doshi2, Nitin Behl3
1School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
概括
萨罗格利塔撒改善了24周内与代谢功能障碍相关的脂肪性肝病 (MASLD) 患者的肝硬度,脂肪症和代谢标志物. 在这个现实世界的中间分析中,双PPARα/γ激动剂表现出良好的耐受性.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 萨罗格利塔撒在印度已被批准用于治疗与代谢功能障碍相关的脂肪性肝病 (MASLD).
- 有控试验显示有效性,但不同人群的真实数据有限.
- 这项研究评估了saroglitazar在MASLD患者的实际有效性和安全性.
研究的目的:
- 评估MASLD患者每天服用4毫克萨罗格利塔萨尔的实际有效性.
- 评估萨罗格利塔萨尔在这个人群中的安全性和耐受性.
- 在治疗24周后,分析肝脏健康和代谢参数的变化.
主要方法:
- 未来的,单臂的,多中心的,现实世界的第四阶段研究.
- 在500名MASLD患者的中期分析中,他们完成了24周的萨罗格利塔萨尔4毫克治疗.
- 评估了肝硬度 (LSM),脂肪酸 (CAP),血糖控制 (HbA1c),脂质概况,肝酶和纤维化得分;通过TEAE进行安全性.
主要成果:
- 在24周后,肝硬度 (-20.7%) 和肥胖症 (CAP -20.3%) 显著减少.
- 在ALT水平 (-33.6%) 和HbA1c (-4.8%) 中显著改善.
- 脂质特征和非侵入性纤维化得分的有利变化;13.6%报告轻度,大多与TEAE无关.
结论:
- 萨罗格利塔萨尔4毫克在真实世界的MASLD队列中显示出肝硬度,胆固醇和代谢参数的显著改善.
- 这种治疗一般都能很好地忍受.
- 这些临时发现支持在计划的52周分析中进一步评估.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
786
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
786
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
739
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
739
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
672
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
672
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
250
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
250
01:06Oral Hypoglycemic Agents: Glinides
758
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
758
01:29Chronic Pancreatitis II: Collaborative Care
435
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
435